Balaji Amines Receives FDA Warning Letter Over Product End-Use; No Financial Impact
Balaji Amines Ltd 路 Others (Uncategorized) 路 01 Oct 2026, 5:45 pm
Balaji Amines Receives FDA Warning Letter Over Product End-Use; No Financial Impact The Food & Drug Administration, Pune, issued a Directions and Warning Letter dated 10th Jan'25 to Balaji Amines after a customer unauthorizedly resold its technical-grade Propylene Glycol for pharmaceutical use, violating the Drugs and Cosmetics Act, 1940. No penalties, prosecution, or adverse orders were levied against the company. Balaji Amines stated there is no material impact on financials or operations and has updated documentation practices by mandating end-use declarations. The disclosure follows a SEBI directive dated 29th Sep'26.
Original exchange filing (PDF)
More announcements from Balaji Amines Ltd
- Submission of Earning Call Transcript under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 路 09 Nov 2026
- Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015-Audio Recording of the Conference Call held on 04th November, 2026 路 05 Nov 2026
- Investor Presentation on Q2FY27 Financial Results 路 04 Nov 2026
- Disclosure under Regulation 30 (2) read with Para A(20) of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirement Regulations) 2015. 路 04 Nov 2026
- Press Release in connection with Un-Audited Financial Results of the Company for the Quarter and Half Year Ended 30th September, 2026 路 03 Nov 2026
- Balaji Amines Limited has submitted to the Exchange, Financial Results for the Quarter and Half Year Ended 30th September, 2026 路 03 Nov 2026
- Un-Audited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended 30th September, 2026 路 03 Nov 2026
- Financial Results for the Quarter and Half Year Ended 30th September, 2026 路 02 Nov 2026
